The researchers developed a novel therapy for cancer patients that harnesses the patient’s own immune system to fight cancer in a natural way. This therapy uses a ‘natural’ T cell response that does not require genetic engineering.
TapImmune Inc., Jacksonville’s publicly traded developer of cancer-fighting immunotherapies, announced in May that it was merging with Minnesota-based Marker Therapeutics Inc., another developer of immunotherapies.
Company developing immunotherapy treatments for cancer up 139 percent this year.
TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments, begin a strategic alliance with Baylor College of Medicine and move to Houston. The stock has more than tripled since the announcement and rose more than 18 percent Friday.
TapImmune will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.
History could be repeating itself and TapImmune (NASDAQ:TPIV) could be Kite 2.0.
TapImmune would consider a partnership deal with a major pharmaceutical firm overseas.
Markers’ platform has shown promise in early clinical trials in lymphoma, acute myeloid leukemia (AML), and multiple myeloma.
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune has entered in a definitive agreement to acquire Marker Therapeutics.